D-1060-2020 Class II Terminated
FDA drug recall D-1060-2020 was initiated by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc on Mar 19, 2020 and is designated Class II. Reason for recall: SubPotent Drug: Low out-of-specification results for assay testing. The recall status is terminated (terminated Sep 22, 2021). Affected quantity: 7416 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 1, 2020
- Initiation Date
- Mar 19, 2020
- Termination Date
- Sep 22, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7416 bottles
Product description
Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associates, Inc., Greenville, SC 29605; NDC 0121-0810-16.
Reason for recall
SubPotent Drug: Low out-of-specification results for assay testing.
Distribution pattern
Nationwide in the USA.
Code information
Lot: BE85, Exp. 11/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1060-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026